OmniSeq News

Dr. Carl Morrison featured in Future of Personal Health

Dr. Morrison, president of OmniSeq℠ Precision Medicine Technology, is featured as a “leading voice” in precision medicine. Buffalo, NY – June 29, 2015—The digital publication Future of Personal Health focuses on precision medicine in an article entitled...

read more

OmniSeq LLC: A Unique Approach to Personalized Medicine

By Alan Rosenhoch, Featuring Carl Morrison, MD, DVM Dr. Carl Morrison is founder, president and chief scientific officer of OmniSeq LLC – a recent Roswell Park Cancer Institute spinoff genomics firm. At Roswell Park, Dr. Morrison continues in his roles as Executive...

read more

Covaris, Inc. and OmniSeq, LLC Today Announced truXTRAC™ FFPE DNA Extraction and Purification Kit as the Method of Choice for Obtaining Clinical-Grade DNA from FFPE Samples for Use with OmniSeq Target℠ Testing

WOBURN, Mass., Sept. 1, 2015 /PRNewswire/ — truXTRAC is a comprehensive novel solution for clinical-grade DNA extraction from Formalin-Fixed, Paraffin-Embedded (FFPE) tissues utilizing Covaris Adaptive Focused Acoustics® (AFA™) technology. The unique focused,...

read more

Follow Us on Twitter

A focused, simple and cost-effective, NY State DoH CLIA approved assay - Enjoy "Searching for OmniSeq MSI NGS" #AACR18 #cancer #Immunotherapy

In light of the discussion @AACR , OmniSeq CEO Mark Gardner discusses why mutational burden is a necessary, but not sufficient indicator for #Cancer #immunotherapy response prediction #AACR18

Visit #omniseq & Integrated Oncology at booth 4208 for #AACR18 Comprehensive Immune Profiling & launch of MSI NGS

Load More...